DRONTAL PLUS FLAVOUR TABLETS FOR DOGS

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

العنصر النشط:

PRAZIQUANTEL, PYRANTEL EMBONATE, FEBANTEL

متاح من:

Bayer Limited

ATC رمز:

QP52AF30

INN (الاسم الدولي):

PRAZIQUANTEL, PYRANTEL EMBONATE, FEBANTEL

جرعة:

50/144/150

الشكل الصيدلاني:

Tablets

نوع الوصفة الطبية :

CAM-Companion Animal Medicine

المجموعة العلاجية:

Canine

المجال العلاجي:

Combinations of tetrahydropyrimidines

الخصائص العلاجية:

Endoparasiticide

الوضع إذن:

Authorised

تاريخ الترخيص:

2009-01-25

خصائص المنتج

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Plus Flavour Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
A light brown to brown, round, flat tablet, cross scored on one side
for oral administration to dogs.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of the following gastrointestinal tapeworms and
roundworms in dogs and puppies.
Ascarids:
_Toxocara canis, Toxascaris leonina_ (adult and late immature forms).
Hookworms:
_Uncinaria stenocephala, Ancylostoma caninum_ (adults)
Whipworms:
_Trichuris vulpis_ (adults)
Tapeworms:
_Echinococcus_ spp.,_ Taenia_ spp.,_ Dipylidium caninum_ (adult and
immature forms)
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As a precautionary measure to prevent
establishment
of
_Echinococcus multilocularis_
in the UK and Ireland it
is
recommended that all dogs and cats entering the country be treated
with praziquantel.
Fleas serve as intermediate hosts for one common type of
tapeworm-_Dipylidium caninum_.
Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
Each tablet contains:
mg per tablet
Febantel
150.0
Pyrantel embonate
144.0
Praziquantel
50.0
EXCIPIENTS
Artificial beef flavour, irradiated
116.5
For the full list of excipients see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_